Randomized Clinical Trial on Ivermectin versus Thiabendazole for the Treatment of Strongyloidiasis 英文参考文献.docVIP

下载本文档

4
0
约3.33万字
约 6页
2017-05-13 发布于上海
举报
版权申诉

Randomized Clinical Trial on Ivermectin versus Thiabendazole for the Treatment of Strongyloidiasis 英文参考文献.doc

1、本文档共6页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Randomized Clinical Trial on Ivermectin versus Thiabendazole for the Treatment of Strongyloidiasis 英文参考文献

RandomizedClinicalTrialonIvermectinversus ThiabendazolefortheTreatmentofStrongyloidiasis ZenoBisoffi1*,DoraBuonfrate1,AndreaAngheben1,MarinaBoscolo1,MariellaAnselmi1 ,Stefania Marocco1,GeraldoMonteiro1,MariaGobbo1,GiuliaBisoffi2,FedericoGobbi1 1CentreforTropicalDiseases,S.CuoreHospital,Negrar(Verona),Italy,2BiostatisticUnit,UniversityHospital,Verona,Italy Abstract Background: Strongyloidiasis may cause a life-threatening disease in immunosuppressed patients. This can only be prevented by effective cure of chronic infections. Direct parasitologic exams are not sensitive enough to prove cure if negative.Weusedanindirectimmunefluorescentantibodytest(IFAT)alongwithdirectmethodsforpatientinclusionand efficacyassessment. Methodology/PrincipalFindings:Prospective,randomized,openlabel,phaseIIItrialconductedattheCentreforTropical Diseases(Verona,Italy)tocompareefficacyandsafetyofivermectin(singledose,200mg/kg)andthiabendazole(twodaily th dosesof25mg/Kgfortwodays)tocurestrongyloidiasis.Thefirstpatientwasrecruitedon6 December,2004.Follow-up visit of the last patient was on 11th January, 2007. Consenting patients responding to inclusion criteria were randomly assignedtooneofthetreatmentarms.Primaryoutcomewas:negativedirectandindirect(IFAT)testsatfollow-up(4to6 monthsaftertreatment)orsubjectswithnegativedirecttestanddropoftwoormoreIFATtiters.Considering198patients who concluded follow-up, efficacy was 56.6% for ivermectin and 52.2% for thiabendazole (p=0.53). If the analysis is restrictedto92patientswithIFATtiter80ormorebeforetreatment(virtually100%specific),efficacywouldbe68.1%for ivermectin and 68.9% for thiabendazole (p=0.93). Considering direct parasitological diagnosis only, efficacy would be 85.7%forivermectinand94.6%forthiabendazole(p=0.21).Inivermectinarm,mildtomoderatesideeffectswereobserved in24/115patients(20.9%),versus79/108(73.1%)inthiabendazolearm(p=0.00). Conclusion:Nosignificantdifferenceinefficacywasobserved,whilesideeffectswerefarmorefrequentinthiaben